SSC 2026 Guidelines now available — 129 adult & 61 pediatric recommendations View guidelines →
Evidence-based guideline for emetogenic risk classification, antiemetic regimen selection, and management of chemotherapy-induced nausea and vomiting.
Patient assessment and grading tools for CINV including CTCAE and MASCC Antiemesis Tool, evidence-based non-pharmacological interventions, guideline implementation strategies, quality improvement metrics, and patient education.
Guideline-recommended antiemetic regimens by emetogenic risk level, multi-day chemotherapy protocols, oral chemotherapy CINV, radiation-induced nausea and vomiting, breakthrough and refractory CINV management, and considerations for pediatric, geriatric, and organ-impaired populations.
Comprehensive review of antiemetic drug classes used in CINV prophylaxis and treatment: NK1 receptor antagonists, 5-HT3 receptor antagonists, corticosteroids, olanzapine, dopamine antagonists, benzodiazepines, and cannabinoids with complete dosing, pharmacokinetics, and adverse effect profiles.
Complete emetogenic risk classification of intravenous and oral chemotherapy agents (high, moderate, low, minimal), types of CINV, pathophysiology of chemotherapy-induced emesis, and patient- and treatment-related risk factors.